- City Therapeutics completes $200 million IPO, earmarks funds for RNAi therapiesCity Therapeutics, based in Cambridge, Massachusetts, launched an IPO raising $200 million, exceeding its original target of 9.7 million shares at $17-$19 per share. The company sold 11.1 million…
- Estuary Biotherapeutics raises $103M to advance gene therapies for polycystic kidney diseaseEstuary Biotherapeutics announced it has exited stealth mode after securing $103 million in financing to move two gene‑therapy candidates into clinical testing for autosomal dominant polycystic kid…